ÐÂÎÅÖÐÐÄ
News Center
ºôÎüÁìÓòÖØ´óÏ£Íû£¡bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾Á¢ÒìÒ©Ê×µÇÅ·ÖÞºôÎüѧ»á¹ú¼Ê´ó»á
Ðû²¼Ê±¼ä£º2024-08-27
9ÔÂ7ÈÕÖÁ11ÈÕ£¬£¬£¬£¬£¬ £¬ £¬µÚ34½ìÅ·ÖÞºôÎüѧ»á¹ú¼Ê´ó»á£¨ERS International Congress 2024£©½«ÔڰµØÀûάҲÄɾÙÐУ¬£¬£¬£¬£¬ £¬ £¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾ºôÎüÁìÓò2¿î1ÀàÁ¢ÒìÒ©TQC3721£¨ÎüÈëÐÔPDE3/4ÒÖÖƼÁ£©¡¢TQC2731£¨TSLPµ¥¿¹£©¹²3ƪÑо¿Ð§¹û½«ÔÚ±¾´Î´ó»áÐû²¼¡£¡£¡£¡£¡£ERS¹ú¼Ê´ó»áÊÇÌìÏÂÉÏ×î´óµÄºôÎüҽѧרҵѧÊõ¾Û»á£¬£¬£¬£¬£¬ £¬ £¬ÕâÊǹ«Ë¾ºôÎüÁìÓòÁ¢ÒìÒ©Ñо¿Êý¾ÝÊ׵ǸÃÏî¹ú¼Ê´ó»á£¬£¬£¬£¬£¬ £¬ £¬±ê¼Ç׏«Ë¾ÔÚºôÎüÁìÓòµÄÑз¢Á¢ÒìÈ¡µÃÍ»ÆÆÐÔÏ£Íû¡£¡£¡£¡£¡£
TQC3721£ºÖйúÑз¢½ø¶È×î¿ìµÄ¹ú²úPDE3/4Ë«ÖØÒÖÖƼÁ
TQC3721ÊÇÒ»¿îPDE3/4Ë«ÖØÒÖÖƼÁ£¬£¬£¬£¬£¬ £¬ £¬ÎªÎüÈëÐÔ»ìÐüÒº£¬£¬£¬£¬£¬ £¬ £¬ÄâÓÃÓÚÖÎÁÆÖÐÖضÈÂýÐÔÛÕ±ÕÐԷβ¡£¡£¡£¡£¡£¨COPD£©¡£¡£¡£¡£¡£ÏÖÔÚ£¬£¬£¬£¬£¬ £¬ £¬º£ÄÚÉÐÎÞͬ°ÐµãÒ©Îï»ñÅúÉÏÊУ¬£¬£¬£¬£¬ £¬ £¬TQC3721ÊÇÖйúÑз¢½ø¶È×î¿ìµÄ¹ú²úPDE3/4Ë«ÖØÒÖÖƼÁ¡£¡£¡£¡£¡£PDE3Ö÷Òª×÷ÓÃÓÚÖ§Æø¹Üƽ»¬¼¡£¡£¡£¡£¡£¬£¬£¬£¬£¬ £¬ £¬PDE4Ö÷ÒªÔÚÖÖÖÖÑ×֢ϸ°ûÖбí´ï£¬£¬£¬£¬£¬ £¬ £¬TQC3721ͨ¹ýË«°ÐµãÒÖÖÆ£¬£¬£¬£¬£¬ £¬ £¬¿ÉÒÔ½µµÍÍÑ°ÐЧӦ£¬£¬£¬£¬£¬ £¬ £¬²¢ÔÚÒ»¸ö»¯ºÏÎïÖÐÍŽáÖ§Æø¹ÜÀ©ÕźͿ¹Ñ×µÄË«ÖØ»îÐÔ¡£¡£¡£¡£¡£
ÏÖÔÚ£¬£¬£¬£¬£¬ £¬ £¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾ÏÂÊôÆóÒµÕý´óÌìÇçÒѾÍê³ÉIÆÚºÍIIaÆÚÁÙ´²ÊÔÑ飬£¬£¬£¬£¬ £¬ £¬2ƪ±Ú±¨ËùÓб»±¾´Î´ó»áÊÕ¼£¬£¬£¬£¬£¬ £¬ £¬ÆäÖÐһƪÒÔ×îÐÂÖØ°õÕªÒª£¨Late Breaking Abstract£©µÄÐÎʽÈëÑ¡¡£¡£¡£¡£¡£
IÆÚ£ºÆÀ¹ÀÎüÈëÓÃTQC3721»ìÐüÒºÇå¾²ÐÔ¡¢ÄÍÊÜÐÔ¡¢Ò©´ú¶¯Á¦Ñ§ÌØÕ÷ºÍÆðÔ´ÁÆЧµÄI ÆÚÁÙ´²ÊÔÑé
Safety, Tolerability and Pharmacokinetics of the Phosphodiesterase 3/4 (PDE3/4) Inhibitor TQC3721 Suspension for Inhalation in Healthy Adult Subjects
IIaÆÚ£ºÆÀ¹ÀÎüÈëÓÃTQC3721»ìÐüÒºÔÚÖÐÖضÈÂýÐÔÛÕ±ÕÐԷβ¡»¼ÕßÖеÄÓÐÓÃÐÔºÍÇå¾²ÐÔµÄËæ»ú¡¢Ë«Ã¤¡¢Î¿½å¼Á±ÈÕÕ¡¢¼ÁÁ¿Ì½Ë÷¡¢¶àÖÐÐÄIIÆÚÁÙ´²ÊÔÑé
Late Breaking Abstract - A Dose-Ranging Study of the Inhaled Dual PDE3/4Inhibitor TQC3721 in COPD Patients
ͨѶ×÷ÕߣºËÄ´¨´óѧ»ªÎ÷Ò½Ôº ÀîΪÃñ ½ÌÊÚ
µÚÒ»×÷ÕߣºËÄ´¨´óѧ»ªÎ÷Ò½Ôº ÂÞÖù ½ÌÊÚ
TQC2731£ºÏø´IIÆÚÁÙ´²½ø¶È×î¿ìµÄ¹ú²úTSLPµ¥¿¹
TQC2731ÊÇÒ»¿îÐØÏÙ»ùÖÊÁÜ°Íϸ°ûÌìÉúËØ(TSLP)µ¥¿¹£¬£¬£¬£¬£¬ £¬ £¬Îª1ÀàÉúÎïÁ¢ÒìÒ©£¬£¬£¬£¬£¬ £¬ £¬ÏÖÔÚÕýÔÚÖйú¿ªÕ¹IIÆÚÁÙ´²ÊÔÑ飬£¬£¬£¬£¬ £¬ £¬Ë³Ó¦Ö¢°üÀ¨ÖضÈÏø´ºÍÂýÐÔ±Çñ¼Ñ×°éÓбÇÏ¢È⣬£¬£¬£¬£¬ £¬ £¬ÊÇÏø´IIÆÚÁÙ´²½ø¶È×î¿ìµÄ¹ú²úTSLPµ¥¿¹¡£¡£¡£¡£¡£ÆäÖУ¬£¬£¬£¬£¬ £¬ £¬ÖضÈÏø´µÄIIÆÚÁÙ´²ÊÔÑéÒÑÍêÓñ³É²¿ÊÜÊÔÕßÈë×é¡£¡£¡£¡£¡£
Ñо¿ÏÔʾ£¬£¬£¬£¬£¬ £¬ £¬TSLPµ¥¿¹²»µ«ÄÜÓÐÓÃÖÎÁÆÊÈËáÐÔÁ£Ï¸°ûÐÔÏø´£¬£¬£¬£¬£¬ £¬ £¬ÔÚÊÈËáÐÔÁ£Ï¸°ûÊýÄ¿½ÏµÍ±íÐ͵ÄÏø´ÈËȺÖУ¬£¬£¬£¬£¬ £¬ £¬ÒàÌåÏÖ³öÏÔÖø»ñÒ棬£¬£¬£¬£¬ £¬ £¬Òò´Ë¿ÉÒÔÁýÕÖÔ½·¢ÆÕ±éµÄÖضÈÏø´»¼Õß¡£¡£¡£¡£¡£´Ë´Î±Ú±¨ÈëÑ¡µÄÑо¿ÊÇIÆÚ¿µ½¡ÈËÑо¿ÕªÒª¡£¡£¡£¡£¡£
ÆÀ¼ÛTQC2731×¢ÉäÒºÔÚ¿µ½¡³ÉÈËÊÜÊÔÕß¼°ÖØÖ¢Ïø´»¼ÕßÖÐËæ»ú¡¢Ë«Ã¤¡¢Î¿½å¼Á±ÈÕյĢñÆÚÁÙ´²ÊÔÑé
Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody TQC2731 targeting thymic stromal lymphopoietin (TSLP) in healthy Chinese adults
ͨѶ×÷ÕߣºÌïöÎ Ö£ÖÝ´óѧµÚÒ»Á¥ÊôÒ½Ôº
µÚÒ»×÷ÕߣºÌïöÎ Ö£ÖÝ´óѧµÚÒ»Á¥ÊôÒ½Ôº
ÏÖÔÚ£¬£¬£¬£¬£¬ £¬ £¬º£ÄÚÉÐÎÞTSLPµ¥¿¹»ñÅúÉÏÊУ¬£¬£¬£¬£¬ £¬ £¬¹«Ë¾½«¶¦Á¦´ó¾ÙÍƽøTQC2731µÄÁÙ´²¿ª·¢£¬£¬£¬£¬£¬ £¬ £¬½â¾öÉÐδ±»Öª×ãµÄÁÙ´²ÐèÇ󡣡£¡£¡£¡£
±¾´Î´ó»áÉÏÐû²¼µÄ3Ïî×îÐÂÑо¿Ð§¹û£¬£¬£¬£¬£¬ £¬ £¬ÖÜȫչʾÁËbevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾ÔÚºôÎüÁìÓòÈ¡µÃµÄÍ»ÆÆÐÔÏ£Íû£¬£¬£¬£¬£¬ £¬ £¬ÎÞÂÛÊÇС·Ö×ÓÎüÈëÒ©£¬£¬£¬£¬£¬ £¬ £¬Õվɴó·Ö×Óµ¥¿¹£¬£¬£¬£¬£¬ £¬ £¬ÎÞÂÛÊÇCOPD£¬£¬£¬£¬£¬ £¬ £¬ÕÕ¾ÉÏø´£¬£¬£¬£¬£¬ £¬ £¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾¶¼¾ÙÐÐÁËÖÜÈ«ÁýÕֵĹÜÏ߽ṹ¡£¡£¡£¡£¡£Î´À´£¬£¬£¬£¬£¬ £¬ £¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾½«ÔÚºôÎüÁìÓòÒ»Á¬·¢Á¦£¬£¬£¬£¬£¬ £¬ £¬Ò»Ö±Ì½Ë÷Á¢ÒìÒ©ÎïÓëÖÎÁƼƻ®¡£¡£¡£¡£¡£
ÉùÃ÷£º
1. ±¾ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷£¬£¬£¬£¬£¬ £¬ £¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬£¬£¬£¬£¬ £¬ £¬·Ç¹ã¸æÓÃ;¡£¡£¡£¡£¡£
2. ±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£¡£¡£¡£¡£
3. ±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬£¬£¬£¬£¬ £¬ £¬²»¿ÉÒÔÈκη½·¨È¡´úרҵµÄÒ½ÁÆÖ¸µ¼£¬£¬£¬£¬£¬ £¬ £¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£¡£¡£¡£¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢£¬£¬£¬£¬£¬ £¬ £¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£¡£¡£¡£¡£
Ç°Õ°ÐÔÉùÃ÷£º
±¾ÐÂΟåÖаüÀ¨Èô¸ÉÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬£¬ £¬ £¬°üÀ¨Óйء¾TQC3721£¨ÎüÈëÐÔPDE3/4ÒÖÖƼÁ£©¡¢TQC2731£¨TSLPµ¥¿¹£©¡¿µÄÁÙ´²¿ª·¢ÍýÏë¡¢ÁÙ´²»ñÒæÓëÓÅÊƵÄÔ¤ÆÚ¡¢ÉÌÒµ»¯Õ¹Íû¡¢»¼ÕßÁÙ´²»ñÒæ¿ÉÄÜÐÔ£¬£¬£¬£¬£¬ £¬ £¬ÒÔ¼°Ç±ÔÚÉÌҵʱ»úµÈÉùÃ÷¡£¡£¡£¡£¡£“Ô¤ÆÚ”¡¢“ÐÅÍД¡¢“¼ÌÐø”¡¢“¿ÉÄÜ”¡¢“Ô¤¼Æ”¡¢“ÆÚÍû”¡¢“ÓÐÍû”¡¢“ÍýÏ딡¢“ÍýÏ딡¢“DZÔÚ”¡¢“Õ¹Íû”¡¢“Ô¤¼Æ”¡¢“Ó¦¸Ã”¡¢“½«”¡¢“Ä┡¢“»á”ºÍÀàËƱí´ïÖ¼ÔÚʶ±ðÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬£¬ £¬ £¬µ«²¢·ÇËùÓÐÇ°Õ°ÐÔ³ÂÊö¶¼°üÀ¨ÕâЩʶ±ð´Ê¡£¡£¡£¡£¡£ÕâЩǰհÐÔ³ÂÊöΪ¹«Ë¾»ùÓÚÄ¿½ñËùÕÆÎÕµÄÊý¾ÝºÍÐÅÏ¢Ëù×öµÄÕ¹Íû»òÆÚÍû£¬£¬£¬£¬£¬ £¬ £¬¿ÉÄÜÒòÊܵ½Õþ²ß¡¢Ñз¢¡¢Êг¡¼°î¿ÏµµÈ²»È·¶¨ÒòËØ»òΣº¦µÄÓ°Ï죬£¬£¬£¬£¬ £¬ £¬¶øµ¼ÖÂÏÖʵЧ¹ûÓëÇ°Õ°ÐÔ³ÂÊöÓÐÖØ´ó²î±ð¡£¡£¡£¡£¡£ÇëÏÖÓлòDZÔÚµÄͶ×ÊÕßÉóÉ÷˼Á¿¿ÉÄܱ£´æµÄΣº¦£¬£¬£¬£¬£¬ £¬ £¬²¢²»¿ÉÍêÈ«ÒÀÀµ±¾ÐÂΟåÖеÄÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬£¬ £¬ £¬¸ÃµÈ³ÂÊö°üÀ¨ÐÅÏ¢½ö¼°ÓÚ±¾ÐÂΟåÐû²¼µ±ÈÕ¡£¡£¡£¡£¡£³ý·ÇÖ´·¨ÒªÇ󣬣¬£¬£¬£¬ £¬ £¬±¾¹«Ë¾ÎÞÒåÎñÒòÐÂÐÅÏ¢¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐζø¶Ô±¾ÐÂΟåÖÐÈκÎÇ°Õ°ÐÔ³ÂÊö¾ÙÐиüлòÐ޸ġ£¡£¡£¡£¡£
ÄÚÈÝȪԴ£ºbevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾ÓÐÏÞ¹«Ë¾ÓÚÏã¸ÛÁª½»ËùÐû²¼µÄͨ¸æ¡¢Õý´óÌìÇçÒ©Òµ¼¯ÍŹ«ÖÚºÅ